Business Wire

Lineage Logistics Announces Lineage Fresh, Expands Fresh Produce Offering In Europe

7.2.2023 20:51:00 EET | Business Wire | Press release

Share

Lineage Logistics, LLC (“Lineage” or the “Company”), one of the leading temperature-controlled industrial REIT and logistics solutions providers worldwide, announced Lineage Fresh, a new strategic service in Europe, launched last November in the US, which provides fresh storage solutions for major importers, grocers, and producers of fresh fruit and produce, as part of its participation in the Fruit Logistica trade show in Berlin.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207006000/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Fresh blueberries are packed at a Lineage facility. (Photo: Business Wire)

Lineage Fresh will allow products with a short shelf-life to face fewer obstacles, less risk, and less spoilage with Lineage’s cold storage technology and leading logistics network. Leveraging the Company’s expertise as a global temperature-controlled storage provider, Lineage Fresh is designed to cater to businesses in which food safety is critical and speed to market is essential. The new value-added services and specialized capabilities of Lineage Fresh include re-pack & bagging services, reconditioning, restacking, restyling, container plugs, multi-temperature zones for produce, cold treatment, fumigation, container drayage, juice processing and blending, and the integration of customs’ bonded facilities.

“Lineage Fresh brings state-of-the-art fresh capacity and product expertise to our expanding European network, and connects the growing fresh produce market with customers across Europe and the world,” said Edwin Wentink, Vice President, Business Development Europe. “Lineage Fresh capitalises on the investments we have made in Kloosterboer Group’s legacy of fresh product expertise and its class leading facilities in Rotterdam and Vlissingen, along with a growing footprint in Southern Europe. We are excited to highlight this new solution as part of our participation in Fruit Logistica in Berlin this year.”

Fresh produce importers, exporters, and the international fresh fruit and vegetable community at large have been experiencing significant service and capacity issues with their fresh products. To address Lineage customers’ needs, Lineage has made significant investment in the space to meet the demands of the fresh market and to create a truly connected ‘fresh’ network.

  • In Europe, over the past two years, Lineage has focused on value-added services needed to handle fresh fruits and vegetables, namely fresh food storage, repacking, bagging, and transportation. The Company started this venture in June 2021 with the acquisition of Kloosterboer Group, which continues to bring a large, long-standing fresh operation to the Lineage network, with fresh facilities in both Rotterdam and Vlissingen.
  • In December 2021, Lineage acquired Sun Valley Cold Storage and its facility in Swedesboro, N.J., expanding its presence in the U.S. Tri-State area, where 80% of U.S. produce enters the country. Sun Valley Cold Storage served the fresh produce market for more than 15 years, with a team of experienced professionals dedicated to handling fresh fruits and vegetables. Lineage is in the process of expanding this facility with 5,000 additional pallets coming online in Q1 2023, leveraging the capacity and expertise of the former Sun Valley and Kloosterboer operations to enhance Lineage’s fresh network globally.
  • Lineage is building a new, state-of-the-art refrigerated storage facility at the port of Savannah, Ga., expected to open in February 2023, completely dedicated to fresh produce. Savannah is the fastest-growing port and largest single container terminal in North America, and the new facility will help cut through port congestion to ensure fewer obstacles in maintaining the freshness of the produce.

To learn more about Lineage Fresh, or to find out how you can partner with Lineage, click here.

About Lineage Logistics

Lineage Logistics is one of the leading temperature-controlled industrial REIT and logistics solutions providers worldwide. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 20 countries across North America, Europe, and Asia-Pacific. Lineage has industry-leading expertise in end-to-end logistical solutions, an unrivaled real estate network, and develops and deploys innovative technology. This helps increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, helps feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was listed as No. 3 in the 2022 CNBC Disruptor 50 list, named a Deloitte US Best Managed Company in 2022, the No. 1 Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change the World list in 2020. (www.lineagelogistics.com)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lineage Logistics
Magnus Franklin
+32471620575                                               
magnus.franklin@teneo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye